Lancashire and South Cumbria
Formulary
5 Infections
This chapter of the formulary has not been published, please use local guidelines.
For more information about the formulary development process, please see:
https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
The formulary development team can be contacted here:
mlcsu.lscformulary@nhs.net
05-03-03 Viral hepatitis
Links
Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older) - Supply Disruption
Central Lancashire/LSCFT/Morecambe Bay Primary Care: NICE Summary of antimicrobial prescribing guidance - managing common infections
East Lancashire Primary Care: Antimicrobial guide primary care
East Lancashire Secondary Care: Antimicrobial guide secondary care
Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (App store)
Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (Google)
MHRA Drug Safety Update: Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone
MHRA Drug Safety Update: Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone
MHRA Drug Safety Update:Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone
MHRA: predicting sepsis, worsening liver function & mortality with boceprevir & telaprevir
MHRA: predictive factors for sepsis, worsening liver function & mortality with boceprevir & telaprevir
NG199: Clostridioides difficile infection: antimicrobial prescribing
NHS England Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and older)
NICE CG165: Hepatitis B (chronic) - incorporates TA96
NICE CG165:Hepatitis B (chronic): diagnosis and management
NICE ES27: COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19
NICE Guidance 2012
NICE NG138: Pneumonia (community-acquired): antimicrobial prescribing
NICE NG139: Pneumonia (hospital-acquired): antimicrobial prescribing
NICE NG141: Cellulitis and erysipelas: antimicrobial prescribing
NICE NG191 COVID-19 rapid guideline: managing COVID-19
NICE NG191 COVID-19 rapid guideline: managing COVID-19
NICE NG224:Urinary tract infection in under 16s: diagnosis and management
NICE NG50: Cirrhosis in over 16s: assessment and management
NICE NG51: Sepsis: recognition, diagnosis and early management
NICE NG78: Cystic fibrosis: diagnosis and management
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
NICE TA153: Entecavir for the treatment of chronic hepatitis B
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
NICE TA253: Boceprevir for the treatment of genotype 1 chronic hepatitis C
NICE TA330 Sofosbuvir for treating chronic hepatitis C
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
NICE TA896:Bulevirtide for treating chronic hepatitis D
NICE TA900:Tixagevimab plus cilgavimab for preventing COVID-19
NICE TA96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
Publication of an interim clinical commissioning policy: Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older).
TA331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
West Lancashire Primary Care: Pan Mersey antimicrobial guide
Key
Full Site